SlideShare a Scribd company logo
  • Upload
  • Home
  • Explore
  • Login
  • Signup
SlideShare a Scribd company logo
  • Home
  • Explore
  • Upload
  • Login
  • Signup

We've updated our privacy policy. Click here to review the details. Tap here to review the details.

×
×
×
×
×
×
Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

7 Followers
22 SlideShares 1 Clipboard 7 Followers 8 Followings
  • Unblock User Block User
22 SlideShares 1 Clipboard 7 Followers 8 Followings

Personal Information
Contact Details
Tags
critical outcome p53 gene cancer ovarian cancer biotech coti-2 drug discovery rosalind chemsas artificial intelligence investor presentation oncology p53 cancer research biotechnology lung cancer drug development cot cotqf gynecological precision medicine personalized medicine clinical trial gene profiling orphan drug big data tsx personalized treatments breast cancer breakthrough life sciences healthcare cantech tsx-v coti kras personalized cancer care treatment options 48 hours in the hub boston cancer care defining personalized cancer care search for a cure companion diagnostics head and neck cancer biopharmaceutical md anderson cancer center equities.com small-cap breakthrough treatment phase 1 ind filing bio investor forum bioinformatics venture $cot #bif13 research and development r&d artificial intelligenc colon cancer pancreas pitchbook
See more
Presentations (20)
See all
Critical Outcome Technologies - Investor Presentation - June 2013
9 years ago • 1967 Views
Critical Outcome BIO Investor Forum
9 years ago • 1622 Views
Critical Outcome Technologies Business & Scientific Updates
9 years ago • 1310 Views
Critical Outcome - Investor Presentation - January 2014
9 years ago • 993 Views
Critical Outcome Investor Presentation - March 2014
9 years ago • 1219 Views
Critical Outcome Technologies - May 2014
8 years ago • 1304 Views
COTI-2 | Reactivating Mutant p53
8 years ago • 2860 Views
Introducing ROSALIND
8 years ago • 2351 Views
Critical Outcome - September 2014
8 years ago • 844 Views
Critical Outcome Technologies at the BIO Investor Forum 2014
8 years ago • 873 Views
A promising advance for many cancers
8 years ago • 741 Views
Pathway to the clinic and beyond
8 years ago • 22264 Views
More than just a potential BREAKTHROUGH treatment for many cancers
8 years ago • 45808 Views
Small-Cap Stars
7 years ago • 2206 Views
Business and Scientific Update
7 years ago • 32803 Views
Critical Outcome investor presentation - November 2015
7 years ago • 1642 Views
Introducing ROSALIND
7 years ago • 16221 Views
2016 Annual General & Special Meeting of Shareholders
6 years ago • 540 Views
COTI Corporate Presentation at Cantech 2017
6 years ago • 855 Views
2017 Annual General & Special Meeting of Shareholders
5 years ago • 396 Views
Documents (2)
COTI-2 Fact Sheet
6 years ago • 404 Views
COTI Overview
6 years ago • 469 Views
Likes (7)
See all
Totally TED
Donna Murray • 7 years ago
Unlocking the Power of Energy Savings
Thermal Energy International Inc. • 6 years ago
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools in endocrine-responsive tumours: a US perspective
European School of Oncology • 11 years ago
Unknown Genes, Community Profiling, & Biotorrents.net
Morgan Langille • 13 years ago
Critical Outcome - Investor Presentation - January 2014
Critical Outcome Technologies Inc. • 9 years ago
Passing the Healthcare Innovation Torch: From Medicinal Chemistry, Through Biotechnology, to Digital Technology - MaRS Future of Medicine
MaRS Discovery District • 9 years ago
Drug Development Life Cycle
Rajendra Sadare • 13 years ago
  • Activity
  • About

Presentations (20)
See all
Critical Outcome Technologies - Investor Presentation - June 2013
9 years ago • 1967 Views
Critical Outcome BIO Investor Forum
9 years ago • 1622 Views
Critical Outcome Technologies Business & Scientific Updates
9 years ago • 1310 Views
Critical Outcome - Investor Presentation - January 2014
9 years ago • 993 Views
Critical Outcome Investor Presentation - March 2014
9 years ago • 1219 Views
Critical Outcome Technologies - May 2014
8 years ago • 1304 Views
COTI-2 | Reactivating Mutant p53
8 years ago • 2860 Views
Introducing ROSALIND
8 years ago • 2351 Views
Critical Outcome - September 2014
8 years ago • 844 Views
Critical Outcome Technologies at the BIO Investor Forum 2014
8 years ago • 873 Views
A promising advance for many cancers
8 years ago • 741 Views
Pathway to the clinic and beyond
8 years ago • 22264 Views
More than just a potential BREAKTHROUGH treatment for many cancers
8 years ago • 45808 Views
Small-Cap Stars
7 years ago • 2206 Views
Business and Scientific Update
7 years ago • 32803 Views
Critical Outcome investor presentation - November 2015
7 years ago • 1642 Views
Introducing ROSALIND
7 years ago • 16221 Views
2016 Annual General & Special Meeting of Shareholders
6 years ago • 540 Views
COTI Corporate Presentation at Cantech 2017
6 years ago • 855 Views
2017 Annual General & Special Meeting of Shareholders
5 years ago • 396 Views
Documents (2)
COTI-2 Fact Sheet
6 years ago • 404 Views
COTI Overview
6 years ago • 469 Views
Likes (7)
See all
Totally TED
Donna Murray • 7 years ago
Unlocking the Power of Energy Savings
Thermal Energy International Inc. • 6 years ago
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools in endocrine-responsive tumours: a US perspective
European School of Oncology • 11 years ago
Unknown Genes, Community Profiling, & Biotorrents.net
Morgan Langille • 13 years ago
Critical Outcome - Investor Presentation - January 2014
Critical Outcome Technologies Inc. • 9 years ago
Passing the Healthcare Innovation Torch: From Medicinal Chemistry, Through Biotechnology, to Digital Technology - MaRS Future of Medicine
MaRS Discovery District • 9 years ago
Drug Development Life Cycle
Rajendra Sadare • 13 years ago
Tags
critical outcome p53 gene cancer ovarian cancer biotech coti-2 drug discovery rosalind chemsas artificial intelligence investor presentation oncology p53 cancer research biotechnology lung cancer drug development cot cotqf gynecological precision medicine personalized medicine clinical trial gene profiling orphan drug big data tsx personalized treatments breast cancer breakthrough life sciences healthcare cantech tsx-v coti kras personalized cancer care treatment options 48 hours in the hub boston cancer care defining personalized cancer care search for a cure companion diagnostics head and neck cancer biopharmaceutical md anderson cancer center equities.com small-cap breakthrough treatment phase 1 ind filing bio investor forum bioinformatics venture $cot #bif13 research and development r&d artificial intelligenc colon cancer pancreas pitchbook
See more

Modal header

  • About
  • Support
  • Terms
  • Privacy
  • Copyright
  • Cookie Preferences
  • Do not sell or share my personal information
English
Current Language: English
Español
Português
Français
Deutsch

© 2023 SlideShare from Scribd

We've updated our privacy policy.

We’ve updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.

You can read the details below. By accepting, you agree to the updated privacy policy.

Thank you!

View updated privacy policy
We've encountered a problem, please try again.